Treating Chronic Fatigue states as a disease of the regulation of energy metabolism

Medical Hypotheses

Volumn 71, Issue 4, 2008, Pages 481-488

  Bains, William ^a  

^a Delta G Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN DERIVATIVE;

ARTICLE; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; DIAGNOSTIC TEST; ENERGY METABOLISM; KINESIOTHERAPY; MITOCHONDRIAL ENERGY TRANSFER; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

COGNITIVE THERAPY; ENERGY METABOLISM; EXERCISE; FATIGUE SYNDROME, CHRONIC; HUMANS; MITOCHONDRIA; MODELS, THEORETICAL;

BACTERIA (MICROORGANISMS);

EID: 50849129544     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.02.022     Document Type: Article

References (89)

1. Wessely S., Hotopf M., and Sharpe M. Chronic Fatigue and its Symptoms (1998), Oxford University Press, Oxford UK
2. Prins J.B., van der Meer J.W., and Bleijenberg G. Chronic fatigue syndrome. Lancet 387 (2006) 346-355
3. Sharpe M.C., Archard L.C., Banatvala J.E., Borysiewicz L.K., Clare A.W., David A., Edwards R.H., Hawton K.E., Lambert H.P., and Lane R.J. A report - chronic fatigue syndrome: guidelines for research. J. Royal Society of Medicine 84 2 (1991) 118-121
4. Fukuda K., Straus S., Hickie I., Sharpe M., Dobbins J.G., and Komaroff A. The chronic fatigue syndrome. Annals of Internal Medicine 121 12 (1994) 853-959
5. Center for Disease Control, Chronic Fatigue Syndrome http://www.cdc.gov/ncidod/diseases/cfs/ (produced by Center for Disease Control, accessed 30th November 2005).
6. Stokes M., Cooper R., and Edwards R.H. Normal strength and fatiguability in patients with effort syndrome. British Medical Journal 297 (1988) 1014-1018
7. Lloyd A., Gandevia S., and Hale J. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with chronic fatigue syndrome. Brain 114 (1991) 85-98
8. Sargent C., Scroop G.C., Nemeth P.M., Burnet R.B., and Buckley F.D. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome. Med. Sci. Sports Exercise. 34 1 (2002) 51-56
9. J Lane R., Woodrow D., and Archard L.C. Lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatry. 57 (1994) 662-663
10. Lane .R.J.M., Barrett M.C., Woodrow D., Moss J., Fletcher R., and Archard L.C. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatry. 64 (1998) 362-367
11. Timmers H.J., Wieling W., Soetekouw P.M., Bleijenberg G., van der Meer J.W., and lenders J.W. Hemodynamic and neuromumoural responses to head-up tilt in patients with chronic fatigue syndrome. Clin. Auton. Res. 12 4 (2002) 273-280
12. Ferrari R., Cicchitelli G., Merli E., Andreadou I., and Guardigli G. Metabolic modulation and optimization of energy consumption in heart failure. Med. Clin. North America 87 2 (2003) 493-507
13. Ventura-Clapier R., De Sousa E., and Veksler V. Metabolic myopathy in heart failure. News Physiol. Science. 17 (2002) 191-196
14. Deluca J., Johnson S.K., Ellis S.P., and Natelson B.H. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psyciatric disease. J. Neurol. Neurosurg. Psychiatry 62 (1997) 151-155
15. Kroenke K., Wood D.R., Mangelsdorff A.D., Meier N.J., Powell J.B., Prevalence C.f.i.p.care., and characteristics p. and outcome. Journal of the American Medical Association 260 7 (1988) 929-934
16. Wilson A., Hickie I., Lloyd A., Hadzi-Pavlovic D., Boughton C., Dwyre J., and Wakefield D. Longitudinal study of outcome of chronic fatigue syndrome. British Medical Journal 308 (1994) 756-759
17. Whiting P., Bagnall A.-M., Sowden A.J., Cornell J.E., Mulrow C.D., and Ramírez G. Interventions for the treatment and management of chronic fatigue syndrome. Journal of the American Medical Association 286 11 (2001) 1360-1368
18. Lloyd A., and Pender H. The economic impact of chronic fatigue syndrome. Med. J. Aust. 157 9 (1992) 599-601
19. Gunn W.J., Connell D.B., and Randall B. Epidemiology of chronic fatigue syndrome: the Centres for Disease COntrol study. Ciba Foundation Symposium 173 (1993) 83-93
20. Lawrie S.M., and Pelosi A.J. Chronic fatigue syndrome in teh community Prevalence and associations. British Journal of Psychiatry 166 (1995) 793-797
21. Jason L.A., Richman J.A., Rademaker A.W., Jordan K.M., Pliophys A.V., Taylor R.R., McCready W., Huang C.F., and Pliophys S. A community-based study of chronic fatigue syndrome. Archives of Internal Medicine 159 18 (1999) 2129-2137
22. Reyes M., Nisenbaum R., Hoaglin D.C., Unger E.R., Emmons C., Randall B., Stewart J.A., Abbey S., Jones J.F., Gantz N., MInden S., and Reeves W.C. Prevalence and incidence of Chronic Fatigue Syndrome in Wichita, Kansas. Archives of Internal Medicine 163 (2003) 1530-1536
23. Buchwald D., Umali P., Umali J., Kith P., Pearlman T., and Komaroff A.L. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Annals of Internal Medicine 123 2 (1995) 81-88
24. Reid S., Chalder T., Cleare A., and Hotopf M. Chronic fatigue syndrome. British Medical Journal 320 7230 (2000) 292-296
25. C. Jackson, Chronic Fatigue Syndrome http://www.patient.co.uk/showdoc/40000806/ (produced by EMIS, accessed 25th Jan 2006).
26. Evengård B., Schacterle R.S., and Komaroff A.L. Chronic fatigue syndrome: new insights and old ignorance. Journal of Internal Medicine 246 (1999) 455-469
27. Borish L., Schmaling K., DiClementi J.D., Streib J., Negri J., and Jones J.F. Chronic fatigue syndrome: identification of distinct subgroups on basis of allergy and psychological variables. Journal of Allergy and Clinical Immunology 102 2 (1998) 222-230
28. Nieman D.C. Is infection risk linked to exercise workload?. Medicine and Science in Sports and Exercise 32 7 (2000) S406-S411
29. Budgett R. ABC of sports medicine. The overtraining syndrome. British Medical Journal 309 (1994) 465-468
30. Budgett R., Newsholme E., Lehmann M., Sharp C., Jones D., Jones T., Peto T., Collins D., Nerurkar R., and White P. Redefining the overtraining syndrome as the unexplained underperformance syndrome. British Journal of Sports Medicine 34 (2000) 67-68
31. Clauw D.J., and Chrousos G.P. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4 3 (1997) 134-153
32. Bagnall A.M., Whiting P., Richardson R., and Sowden A.J. Interventions for the treatment and management of chronic fatigue syndrome myalgic encephalomyelitis. Qual. Saf. Health Care 11 (2002) 284-288
33. Reid S., Chalder T., Cleare A., Hotopf M., and Wessely S. Chronic fatigue syndrome. Clinical Evidence 15 (2005) 1-3
34. Straus S.E. Pharmacotherapy of chronic fatigue syndrome. Journal of the American Medical Association 292 10 (2004) 1234-1235
35. Wessely S., David A., Butler S., and Chalder T. Management of chronic (post-viral) fatugue syndrome. Journal of the Royal COllege of General Practitioners 39 318 (1989) 26-29
36. Wessely S., and Powell R. Fatigue syndromes: a comparision of chronic 'postviral' fatigue with neuromuscular and affective disorders'. J. Neurol. Neurosurg. Psychiatry 52 (1989) 940-948
37. Natelson B.H. Chronic Fatigue Syndrome. Journal of the American Medical Association. 285 20 (2003) 2557-2559
38. Skapinakis P., Lewis G., and Meltzer H. Clarifying the relationship betweenunexplained chronic fatigue and psychiatric morbidity: results from a community survey in Great Britain. American Journal of Psychiatry 157 (2000) 1492-1498
39. Lane T.J., Manu P., and Matthews D.A. Depression and somatization in the chronic fatigue syndrome. American Journal of Medicine 91 4 (1991) 335-344
40. Fuhrer R., and Wessely S. The epidemiology of fatugue and depression: a French primary-care study. Psychological Medicine 25 5 (1995) 895-905
41. Taylor R.R., Jason L.A., and Jahn S.C. Chronic fatigue and sociodemographic characteristics as predictors of psychiatric disorders in a community-based sample. Psychosomatic medicine 65 (2003) 896-901
42. Vercoulen J.H., Swanink C.M., Zitman F.G., Vreden S.G., Hoofs S.G., Fennis J.F., Galama J.M., van der Meer J.W., and VBleijenberg G. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 347 9005 (1996) 858-861
43. Wearden A.J., Morriss R.K., Mullis R., Strickland P.L., Pearson D.J., Appleby L., Campbell I.T., and Morris J.A. Randomised double-blind placebo-cntrolled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. British Journal of Psychiatry 172 (1998) 485-490
44. Blacker C.V., Greenwood D.T., Wesnes K.A., Wilson R., Woodward C., Howe I., and Ali T. Effect of galantamine hydrochloride in chronic fatigue syndrome: a randomized controlled trial. Journal of the American Medical Association 292 10 (2004) 1195-1204
45. Moss R.B., Mercandetti A., and Vojdani A. TNF-alpha and chronic fatigue syndrome. Journal of Clinical Immunology 19 5 (1999) 314-316
46. Cannon J.G., Angel J.B., Adad L.W., O'Grady J., Lundgrem N., Fagioli L., and Komaroff A.L. Hormonal influences on stress-induced neutrophil mobilixation in health and chronic fatigue syndrome. Journal of Clinical Immunology 18 4 (1998) 291-298
47. Lloyd A., Hickie I., Brockman A., Hickie C., Wilson A., Dwyer J., and Wakefield D. Immunologic and psychologicl therapy for patients with chronic fatigue syndrome: a double-blind placebo-controlled trial. American Journal of Medicine 94 2 (1993) 197-203
48. Steinberg P., McNutt B.E., Marshall P., Schenk C., Lurie N., Pheley A., and Petersen P.K. Double blind placebo-controlled study of the efficacy oforal terfenadine in the treatment of chronic fatigue syndrome. J. Allergy and clinical immunology 97 1 (1996) 119-126
49. Rasmussen A.K., Andersen V., Nielsen H., and Wiik A. Chronic fatigue syndrome - a defined unity?. Ugeskr Laeger 157 6 (1995) 756-757
50. Demitrack M.A., Dale J.K., Straus S.E., Laue L., Listwak S.J., Kruesi M.J., Chrousos G.P., and Gold P.W. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. Journal of Clinical Endocrinology and Metabolism 73 (1991) 1224-1234
51. Adler G.K., Manfredsdottir V.F., and Rackow R.M. Hypothalamic-pituitary-adrenal axis function in fibromyalgia and chronic fatigue syndrome. The Endocrinologist 12 6 (2002) 513-524
52. Kavelaars A., Kuis W., Knook L., Sinnema G., and Heijnen C.J. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 85 (2000) 692-696
53. Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome anorexia nervosa and major depression. Medical Hypotheses 65 2 (2005) 287-295
54. Cleare A. The neuroendocrinology of chronic fatigue syndrome. Endocrinology Reviews 24 (2003) 236-252
55. Shin J.I., and Lee J.S. Can chronic fatigue symptoms associated with nutcracker phenomenon be treated with aspirin?. Medical Hypotheses 69 3 (2007) 704-705
56. Gharibzadeh S., and Hoseini S.S. Is there any relation between moldy building exposure and chronic fatigue syndrome?. Medical Hypotheses 66 6 (2006) 1243-1244
57. Miller R. Thimerosal micromercurialism and chronic fatigue syndrome. Medical Hypotheses. 64 5 (2005) 1063-1064
58. Buskila D., and Press J. Neuroendocrine mechanisms in fibromyalgia - chronic fatigue. Best practice and research clinical rheumatology' 15 5 (2001) 747-758
59. Janal M.N., Ciccone D.S., and Natelson B.H. Sub-typing CFS patients on the basis of 'minor' symptoms. Biological Psychiatry 73 2 (2006) 124-131
60. Ciccone D.S., and Natelson B.H. Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis'. Psychosomatic medicine 65 (2003) 268-275
61. McCully K.K., Natelson B.H., Iotti S., and Sisto S. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 19 5 (1996) 621-625
62. McCully K.K., and Natelson B.H. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clinical Science 97 (1999) 603-608
63. McCully K.K., Smith S., Rajaei S., Leigh Jr. J.S., and Natelson B.H. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J. Applied Physiology 96 (2003) 871-878
64. Behan W.M., More I.A., and Behan P.O. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathologica 83 1 (1991) 61-65
65. Lieberman J., and Bell D.S. Serum angiotensin-converting enzyme as a marker for the chronic fatigue-immune dysfunction syndrome: a comparison to serum angiotensin-converting enzyme in sarcoidosis. American Journal of Medicine 95 4 (1993) 407-412
66. Vladutiu G.D., and Natelson B.H. Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle Nerve 30 1 (2004) 38-43
67. Bakheit A.M., Behan P.O., Watson W.S., and Morton J.J. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol. Scand. 87 3 (1993) 234-238
68. Cinti S., Cancello R., Zingaretta M.C., Ceresi E., de Matteis R., Giordano A., Himms-Hagen J., and Ricquier D. CL316243 and cold stress induce heterogenous expression of UCP-1 mRNA and protein in rodent brown adipocytes. Journal of histochemistry and cytochemistry 50 (2002) 21-32
69. Hansen J.B., Jørgensen C., Petersen R.K., Hallenborg P., de Matteis R., Bøye H.A., Petrovic N., Enerbäck S., Nedergaard j., Cinti S., te Riele H., and Kristiansen K. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. Proc. Nat. Acad. Sci. 101 12 (2004) 4112-4117
70. Nagase I., Yoshida T., Kumamoto K., Umekawa T., Sakane N., Nikami H., Kawada T., and Saito M. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta-3 adrenergic agonist. J. Clin. Invest. 97 12 (1996) 2898-2904
71. Jimenez M., Barbatelli G., Allevi R., Cinti S., Seydoux J., Giacobino J.-P., Muzzin P., and Preitner F. Beta-3-adrenoceptor knockout in C57BL/6J mice depresses the occurence of brown adipocytes in white fat. European Journal of Biochemistry 270 (2003) 699-705
72. Wu H., Kanatous S.B., Thurmond F.A., Gallardo T., Isotani E., Bassel-Duby R., and Williams R.S. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296 5566 (2002) 349-352
73. Vinson G.P., HMehta J., Evans S., Matthews S., Puddefoot J.R., Saridogan E., Holt W.V., and Djahanbakhch O. Angiotensin II stimulates sperm motility. Regulatory Peptides 67 2 (1996) 131-135
74. Ball B.A., Gravance C.G., Wessel M.T., and Sabeur K. Activity of angiotensin-converting enzyme (ACE) in reproductive tissues of the stallion and effects of angiotensin II on sperm motility. Theriogenology 59 3-4 (2003) 901-914
75. Montgomery H., Marshall R., Hemingway H., Myserson S., Clarkson P., Dollery C., Hayward M., Holliman D.E., Jubb M., Thomas E.L., Brynes A.E., Saeed N., Barnard M., Bell J.D., Prasad K., Rayson M., Talmud P.J., and Humphries S. Human gene for physical performance. Nature 393 (1998) 221-222
76. Alvarez R., Terrados N., Ortolana R., Iglesias-Cubero G., Reguero J.R., Batalla A., Cortina A., Fernández-Garcia B., Rodriguez C., Socorro B., Alvarez V., and Coto E. Genetic variation in the renin-angiotensin system and athletic performance. European Journal of Applied Physiology 82 1-2 (2000) 117-120
77. Jones A., Montgomery H., and Woods D.R. Human performance: a role for the ACE genotype?. Sports Science Review 30 4 (2002) 184-190
78. Kennedy G., Spence V.A., McLaren M., Hill A., Underwood C., and Belch J.J.F. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free radical biology and medicine 39 (2005) 584-589
79. de Grey A.D. A proposed refinement of the mitochondrial free radical theory of ageing. Bioessays 19 2 (1997) 161-166
80. de Grey A.D. A mechanism proposed to explain the rise in oxidative stress during aging. Journal of Anti-ageing medicine 1 1 (1998) 53-66
81. Newsholme E., and Stark C. Regulation in metabolism (1973), Wiley, Winchester UK
82. Naschitz J.E., Dreyfuss D., Yeshurun D., and Rosner I. Midodrine treatment for chronic fatugue syndrome. Postgraduate Medicine 80 (2004) 230-232
83. Walker, et al., nuclear M.p.c.r.f.s.q.o.h. mitochindrial and male Y-chromosome DNA: application in human identification. Analytical Biochemistry 337 1 (2005) 89-97
84. Alonso, et al. Real-time PCR designs to estimate nuclear and mitochondrial DNA copy number in forensic and ancient DNA studies. Forensic Science International 139 2-3 (2004) 141-149
85. Emaus R.K., et al. Biochim. Biophys Acta 850 3 (1986) 436-448
86. Feeney, et al. Journal of Neurosciences 125 1-2 (2003) 13-25
87. Bennett J.A., Smyth E.T., Pavord I.D., Wilding P.J., and Tattersfield A.E. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 49 (1994) 771-774
88. Lipworth B.J., Newnham D.M., Clark R.A., Dhillon D.P., Winter J.H., and McDevitt D.G. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 50 (1995) 54-61
89. Rosenborg J., Bengtsson T., Larsson P., Blomgren A., Persson G., and Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. European Journal of CLinical Pharmacology 56 5 (2000) 363-370